aTyr Pharma (ATYR) vs Jasper Therapeutics (JSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
aTyr Pharma (ATYR) has outperformed Jasper Therapeutics (JSPR) over the past year, losing 74.2% versus a loss of 76.7%. Over five years, ATYR leads with a -97.2% price change compared with -99.7% for JSPR. aTyr Pharma is the larger company by market cap ($24.1 million vs $19.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATYR | JSPR |
|---|---|---|
| Share price | $0.2462 | $0.5702 |
| Market cap | $24.15M | $18.97M |
| 1-day change | -3.56% | +1.82% |
| YTD return | -68.56% | -69.40% |
| 1-year return | -74.17% | -76.67% |
| 5-year return | -97.17% | -99.66% |
| EPS (TTM) | $-0.62 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.12 | $2.69 |
| 52-week low | $0.246 | $0.315 |
| Distance from 52-week high | -78.02% | -78.80% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1061.66% | +3407.54% |
| Average volume | 3.24M | 1.37M |
| Shares outstanding | 98.09M | 33.27M |
| Employees | 58 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
ATYR vs JSPR FAQ
Which is bigger, aTyr Pharma or Jasper Therapeutics?
aTyr Pharma (ATYR) is larger, with a market capitalization of $24.15M compared with $18.97M for Jasper Therapeutics (JSPR).
Which stock has performed better over the past year, ATYR or JSPR?
ATYR returned -74.17% over the past 12 months, compared with -76.67% for JSPR (price return, excluding dividends). Past performance does not predict future results.
Are aTyr Pharma and Jasper Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.